Fastest Growing Stocks
APLS is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
APELLIS PHARMACEUTICALS INC (APLS) Stock Price & Overview
NASDAQ:APLS • US03753U1060
Current stock price
40.41 USD
+0.02 (+0.05%)
At close:
40.41 USD
0 (0%)
After Hours:
The current stock price of APLS is 40.41 USD. Today APLS is up by 0.05%. In the past month the price increased by 100.55%. In the past year, price increased by 102.35%.
APLS Key Statistics
52-Week Range16.1 - 40.48
Current APLS stock price positioned within its 52-week range.
1-Month Range16.83 - 40.48
Current APLS stock price positioned within its 1-month range.
- Market Cap
- 5.166B
- P/E
- 310.85
- Fwd P/E
- N/A
- EPS (TTM)
- 0.13
- Dividend Yield
- N/A
APLS Stock Performance
Today
+0.05%
1 Week
+129.08%
1 Month
+100.55%
3 Months
+56.26%
Longer-term
6 Months +69.79%
1 Year +102.35%
2 Years -8.55%
3 Years -51.56%
5 Years -20.25%
10 Years N/A
APLS Stock Chart
APLS Stock Screens
APLS currently appears in the following ChartMill screener lists.
Strong Momentum Stocks
APLS is part of our Strong Momentum Stocks screen, indicating it has an already in confirmed uptrend.
Overbought Stocks
APLS appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
RSI Overbought Stocks
APLS is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
APLS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to APLS. When comparing the yearly performance of all stocks, APLS is one of the better performing stocks in the market, outperforming 94.03% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
APLS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to APLS. APLS has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
APLS Earnings
On February 24, 2026 APLS reported an EPS of -0.47 and a revenue of 199.91M. The company missed EPS expectations (-21.01% surprise) and missed revenue expectations (-1.86% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.47
Revenue Reported199.913M
EPS Surprise -21.01%
Revenue Surprise -1.86%
APLS Forecast & Estimates
29 analysts have analysed APLS and the average price target is 34.17 USD. This implies a price decrease of -15.44% is expected in the next year compared to the current price of 40.41.
For the next year, analysts expect an EPS growth of -1013.25% and a revenue growth -14.42% for APLS
Analysts
Analysts78.62
Price Target34.17 (-15.44%)
EPS Next Y-1013.25%
Revenue Next Year-14.42%
APLS Groups
Sector & Classification
APLS Financial Highlights
Over the last trailing twelve months APLS reported a non-GAAP Earnings per Share(EPS) of 0.13. The EPS increased by 108.97% compared to the year before.
Income Statements
Revenue(TTM)1.00B
Net Income(TTM)22.39M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.23% | ||
| ROA | 2.08% | ||
| ROE | 6.05% | ||
| Debt/Equity | 0.98 |
Chartmill High Growth Momentum
EPS Q2Q%-62.07%
Sales Q2Q%-5.94%
EPS 1Y (TTM)108.97%
Revenue 1Y (TTM)28.46%
APLS Ownership
Ownership
Inst Owners98.77%
Shares127.83M
Float107.42M
Ins Owners4.02%
Short Float %21.35%
Short Ratio8.49
APLS Latest News, Press Relases and Analysis
a day ago - By: Chartmill
APLS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APLS
Company Profile
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 733 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Company Info
IPO: 2017-11-09
APELLIS PHARMACEUTICALS INC
100 Fifth Avenue
Waltham MASSACHUSETTS 02451 US
CEO: Cedric Francois
Employees: 733
Phone: 16179775700
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you describe the business of APELLIS PHARMACEUTICALS INC?
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 733 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
What is the stock price of APELLIS PHARMACEUTICALS INC today?
The current stock price of APLS is 40.41 USD. The price increased by 0.05% in the last trading session.
Does APELLIS PHARMACEUTICALS INC pay dividends?
APLS does not pay a dividend.
What is the ChartMill rating of APELLIS PHARMACEUTICALS INC stock?
APLS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in APELLIS PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APLS.
Can you provide the number of employees for APELLIS PHARMACEUTICALS INC?
APELLIS PHARMACEUTICALS INC (APLS) currently has 733 employees.
Can you provide the short interest for APLS stock?
The outstanding short interest for APELLIS PHARMACEUTICALS INC (APLS) is 21.35% of its float.